Victory Capital Management Inc. Decreases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Victory Capital Management Inc. cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 40.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,752,687 shares of the biopharmaceutical company's stock after selling 1,196,519 shares during the period. Victory Capital Management Inc. owned about 0.60% of Amicus Therapeutics worth $24,871,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of FOLD. Van ECK Associates Corp grew its stake in Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 873 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Amicus Therapeutics by 97.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 3,638 shares during the last quarter. Park Avenue Securities LLC acquired a new stake in Amicus Therapeutics in the 3rd quarter valued at approximately $128,000. Campbell & CO Investment Adviser LLC acquired a new stake in Amicus Therapeutics in the 3rd quarter valued at approximately $134,000. Finally, Los Angeles Capital Management LLC bought a new position in Amicus Therapeutics in the 3rd quarter worth approximately $158,000.

Amicus Therapeutics Price Performance

NASDAQ:FOLD traded down $0.66 during mid-day trading on Thursday, reaching $9.48. 6,314,958 shares of the company were exchanged, compared to its average volume of 3,006,631. Amicus Therapeutics, Inc. has a 12 month low of $9.24 and a 12 month high of $14.57. The stock has a market cap of $2.81 billion, a PE ratio of -18.33 and a beta of 0.80. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 2.42. The company has a fifty day moving average of $11.35 and a 200 day moving average of $11.98.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The business had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. On average, research analysts anticipate that Amicus Therapeutics, Inc. will post 0.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on FOLD. JPMorgan Chase & Co. reduced their target price on shares of Amicus Therapeutics from $21.00 to $19.00 and set an "overweight" rating for the company in a research note on Monday, March 18th. Cantor Fitzgerald reissued an "overweight" rating and set a $22.00 price objective on shares of Amicus Therapeutics in a report on Thursday, February 29th.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 4,167 shares of the company's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $58,338.00. Following the sale, the chief executive officer now owns 871,219 shares in the company, valued at $12,197,066. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total value of $75,525.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,928,605.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bradley L. Campbell sold 4,167 shares of the business's stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the completion of the sale, the chief executive officer now directly owns 871,219 shares of the company's stock, valued at approximately $12,197,066. The disclosure for this sale can be found here. In the last quarter, insiders have sold 55,208 shares of company stock valued at $732,930. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.